Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-2: Phase 3 Garetosmab in Children and Adolescents with Fibrodysplasia Ossificans Progressiva
jRCT2031250302Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP) (3 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events and Serum garetosmab concentrations over time. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on jRCT2031250302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250302.